How to Get Trulicity in Iowa: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why Iowa Patients Request It

Trulicity is a brand-name formulation of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. It is delivered once weekly as a subcutaneous injection using a pre-filled, single-dose pen. The FDA first approved it in September 2014 for glycemic control in adults with type 2 diabetes, and the agency expanded the label in 2020 to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

The mechanism is straightforward: dulaglutide binds GLP-1 receptors in the pancreas, gut, and brain, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Because insulin release is glucose-dependent, hypoglycemia risk is low when dulaglutide is used as monotherapy [2].

Iowa prescribers write dulaglutide for two overlapping patient groups: those who need better HbA1c control beyond metformin or sulfonylurea therapy, and those with type 2 diabetes plus atherosclerotic cardiovascular disease who need a proven cardiovascular risk-reduction agent. The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet reported a 12% relative risk reduction in the composite MACE endpoint (nonfatal MI, nonfatal stroke, or cardiovascular death) with dulaglutide 1.5 mg weekly versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) [3]. That cardiovascular data now drives a significant portion of Iowa prescriptions, particularly in older patients with comorbid coronary artery disease.

Available doses are 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg weekly. Most prescribers in Iowa start patients at 0.75 mg for 4 weeks to minimize gastrointestinal side effects, then titrate to 1.5 mg as the maintenance dose. The 3 mg and 4.5 mg doses, approved by the FDA in 2020, are options when additional glycemic or weight benefit is needed [1].

Who Can Prescribe Trulicity in Iowa

Any licensed prescriber with full prescriptive authority can write for Trulicity in Iowa. That includes MDs and DOs, but also nurse practitioners (NPs) operating under Iowa's full practice authority statute (Iowa Code Chapter 152) and physician assistants (PAs) prescribing under a supervision agreement. Iowa granted NPs full independent practice authority effective July 1, 2016, meaning an NP does not need a collaborating physician signature to prescribe dulaglutide [4].

Pharmacists with advanced prescriptive authority, operating under a collaborative practice agreement, may also prescribe dulaglutide within the terms of that agreement.

The practical implication: Iowa patients are not limited to endocrinologists. Primary care physicians, internal medicine practitioners, NPs at retail clinics, and telehealth prescribers all have legal authority to start Trulicity. The American Diabetes Association 2024 Standards of Care state that "GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk" and place dulaglutide in that preferred category [5].

How Telehealth Prescribing Works in Iowa

Iowa permits telehealth prescribing for Trulicity. Specifically, prescribers can evaluate patients via synchronous audio-video visits and write non-controlled substance prescriptions without an in-person examination, provided the visit meets the standard of care that would apply in an in-person setting. Iowa Admin. Code rule 653-13.11 governs physician telehealth conduct, and parallel rules apply to NPs under the Iowa Board of Nursing [6].

Telehealth platforms operating in Iowa must hold a valid Iowa prescriber license or employ/contract with Iowa-licensed clinicians. Several national GLP-1 telehealth companies are actively prescribing in Iowa as of mid-2025. A typical telehealth visit for Trulicity proceeds as follows:

1. Patient completes an intake questionnaire covering diabetes diagnosis, current medications, cardiovascular history, personal or family history of medullary thyroid carcinoma (MTC), and relevant labs.
2. A synchronous video visit (typically 20 to 30 minutes) occurs with a licensed Iowa clinician.
3. If appropriate, the prescriber sends the prescription electronically to a preferred Iowa pharmacy or a mail-order pharmacy licensed in Iowa.
4. The prescriber orders any outstanding baseline labs and schedules a follow-up at 4 to 8 weeks.

One critical point: telehealth prescribers must verify that the patient does not have a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which are contraindications listed in the FDA label [1]. This screening is done via intake questionnaire and verbal confirmation during the visit.

The HealthRX clinical team uses a standardized Iowa Telehealth Eligibility Framework for GLP-1 initiation that scores patients on five criteria: confirmed type 2 diabetes diagnosis (fasting glucose >126 mg/dL on two occasions, or HbA1c ≥6.5%, or OGTT ≥200 mg/dL), absence of MTC/MEN 2 contraindications, baseline renal function (eGFR ≥15 mL/min/1.73m² required), current medication reconciliation, and cardiovascular risk stratification. Patients who score eligible on all five proceed directly to prescription; those with one borderline criterion are referred for in-person endocrinology evaluation before initiation.

What Labs Are Required Before Starting Trulicity in Iowa

Baseline labs are not legally mandated before a prescriber writes for dulaglutide, but evidence-based practice and most insurer prior authorization forms require them. The following panel is standard across Iowa prescribers and telehealth platforms [5]:

HbA1c. Confirms the type 2 diabetes diagnosis and establishes the baseline from which treatment response is measured. An HbA1c ≥6.5% on two separate occasions meets ADA diagnostic criteria [5].

Comprehensive metabolic panel (CMP). Assesses renal function (creatinine, eGFR) and hepatic function. Dulaglutide does not require dose adjustment for renal impairment, but eGFR below 15 mL/min/1.73m² has not been studied and warrants caution. Hepatic impairment does not require dose adjustment either, but baseline values support safe monitoring [1].

Fasting lipid panel. Not required by the FDA label, but most Iowa commercial insurer PA forms for Trulicity request it as part of cardiovascular risk documentation.

Fasting glucose. Supports diagnosis and monitors for hypoglycemia risk when combined with sulfonylureas or insulin.

Thyroid function tests (TSH). Not required by the label, but clinicians routinely order TSH to rule out concurrent thyroid pathology before initiating a drug that carries a boxed warning about thyroid C-cell tumors in rodents.

Urinalysis with microalbumin-to-creatinine ratio. Ordered when diabetic nephropathy screening is indicated, typically at diabetes diagnosis or annually thereafter per ADA guidelines [5].

Iowa telehealth platforms generally request that patients upload recent lab results (within 12 months for stable patients, within 3 months for those with known CKD or hepatic disease) before the prescribing visit. If labs are unavailable, most platforms order them through a national reference lab with Iowa draw sites (LabCorp or Quest Diagnostics both have locations in Des Moines, Cedar Rapids, Davenport, and Sioux City) before finalizing the prescription [7].

Prior Authorization for Trulicity in Iowa

Most Iowa commercial insurance plans require prior authorization (PA) before covering Trulicity. Iowa Medicaid does not currently cover dulaglutide for type 2 diabetes. Patients on Iowa Medicaid should discuss alternatives with their prescriber, including metformin, glipizide, or other formulary options.

For commercial plans, the PA process typically requires:

• Diagnosis documentation. ICD-10 code E11.x (type 2 diabetes mellitus) with HbA1c value, date of draw, and performing lab.
• Step therapy failure. Most Iowa BlueCross BlueShield, Wellmark, and UnitedHealthcare plans require documented trial and failure of at least one first-line agent, typically metformin at maximally tolerated doses for 90 days, before approving a GLP-1 agonist [8].
• Clinical rationale. For cardiovascular indication, documentation of established ASCVD (myocardial infarction, stroke, peripheral artery disease) or multiple risk factors, supported by the REWIND cardiovascular outcome trial data [3].
• Prescriber information. NPI, DEA (if applicable), practice address, and phone/fax.

The PA form is submitted by the prescribing clinician or their staff. Telehealth platforms operating in Iowa typically have in-house PA teams who manage this process. Standard turnaround is 3 to 5 business days for non-urgent PA requests; urgent or expedited reviews can resolve in 24 to 72 hours under Iowa Insurance Division rules [9].

If the PA is denied, the prescriber may file a peer-to-peer review request or a formal appeal. The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm explicitly supports GLP-1 agonist use in patients with type 2 diabetes and cardiovascular disease as a Category A recommendation, which carries weight in appeal letters [10].

Iowa Pharmacy Access and Dispensing Options

Retail pharmacies across Iowa stock Trulicity in all four dose strengths (0.75 mg, 1.5 mg, 3 mg, and 4.5 mg single-dose pens). Major chains with consistent Iowa inventory include Hy-Vee Pharmacy, CVS, Walgreens, and Walmart Pharmacy. Independent pharmacies in rural Iowa counties may need 24 to 48 hours to order less common doses (3 mg and 4.5 mg) if they are not in regular rotation.

Mail-order pharmacies. Iowa-licensed mail-order pharmacies can ship Trulicity to Iowa addresses. CVS Caremark, Express Scripts, and Optum Rx all ship cold-chain medications to Iowa with next-day or two-day delivery. Trulicity ships refrigerated (2 to 8 degrees Celsius) and can remain at room temperature (not exceeding 30 degrees Celsius) for up to 14 days after first removal from refrigeration [1].

503A compounding pharmacies. Iowa-licensed 503A compounding pharmacies can prepare compounded dulaglutide. 503A pharmacies are patient-specific, licensed under state pharmacy boards, and distinct from 503B outsourcing facilities. Compounded dulaglutide is not FDA-approved and is not bioequivalent-tested against Trulicity, so clinical outcomes data from REWIND and other trials do not directly apply to compounded versions [11]. Patients considering 503A compounded dulaglutide should confirm the pharmacy holds an active Iowa Board of Pharmacy license and that the compounding is done from a USP-verified active pharmaceutical ingredient source.

The FDA issued guidance in May 2023 noting that semaglutide (a related GLP-1 agonist) had been added to the shortage list, making 503A compounding permissible for that drug. As of mid-2025, dulaglutide (Trulicity) is not on the FDA drug shortage list, which means 503A compounding of dulaglutide occupies a more nuanced regulatory position. Iowa prescribers should verify current shortage status before directing patients to a 503A compounder for dulaglutide [12].

Cost, Savings Programs, and Affordability in Iowa

The list price for a 4-week supply of Trulicity (four single-dose pens) is approximately $900 to $950 without insurance as of 2025. Iowa patients have several cost-reduction options:

Eli Lilly Trulicity Savings Card. Commercially insured patients who are not on government programs (Medicare, Medicaid, TRICARE) may pay as little as $25 per month through Lilly's co-pay savings program. The program caps monthly savings at $150 for a 30-day supply [13].

Lilly Cares Foundation. Uninsured or underinsured Iowa patients with income at or below 400% of the federal poverty level may qualify for free Trulicity through Lilly's patient assistance program. Applications are submitted by the prescriber or the patient through the Lilly Cares portal [13].

Iowa Medicaid exclusion. Iowa Medicaid's current preferred drug list does not include dulaglutide for type 2 diabetes. Patients enrolled in Iowa Medicaid who cannot afford branded Trulicity should discuss alternative GLP-1 agonists or other diabetes regimens with their prescriber.

GoodRx and discount cards. GoodRx pricing at Iowa pharmacies for a 4-pen (4-week) supply of Trulicity 1.5 mg ranges from approximately $700 to $850 depending on pharmacy. This is not a substitute for insurance coverage but can reduce out-of-pocket costs for uninsured patients not eligible for Lilly Cares.

How Long Does It Take to Receive Trulicity in Iowa

Timeline from first telehealth visit to first injection depends on whether prior authorization is required.

Without prior authorization (self-pay or plan with open formulary): The prescribing visit takes 20 to 30 minutes. The e-prescription reaches the pharmacy within minutes. A local Iowa pharmacy fills same-day or next business day. A mail-order pharmacy ships within 1 to 2 business days with cold-chain packaging. Total time: 1 to 3 business days.

With prior authorization: Add 3 to 5 business days for standard PA review, or 1 to 3 business days for expedited review. If PA is approved, the pharmacy fills within 24 hours. Total time: 4 to 8 business days from visit to first dose.

If PA is denied and appealed: Appeals add 14 to 30 days depending on the insurer's internal timeline and whether an external review is required under Iowa Insurance Division rules [9].

The ADA recommends initiating cardiovascular risk-reducing therapy "without delay" in patients with type 2 diabetes and established ASCVD, which makes the expedited PA pathway clinically appropriate for that population [5].

Transferring a Trulicity Prescription to Iowa

Iowa patients moving from another state or switching pharmacies can transfer a Trulicity prescription. Under Iowa pharmacy law, a retail pharmacist can transfer a prescription from an out-of-state pharmacy for a non-controlled substance such as dulaglutide, provided the original prescription has remaining refills.

The receiving Iowa pharmacy contacts the originating pharmacy directly. The patient provides the originating pharmacy name, phone number, and prescription number. Transfer is typically completed within 2 to 4 hours during business hours.

If the original prescription has no refills remaining, the patient needs a new prescription from an Iowa-licensed prescriber, including an Iowa-licensed telehealth prescriber. A medical records release from the previous provider, showing diabetes diagnosis and prior medication history, speeds up the new prescribing visit significantly.

Monitoring After Starting Trulicity in Iowa

Starting Trulicity is not the endpoint. Ongoing monitoring is necessary to confirm efficacy, detect side effects early, and meet insurer continuation criteria.

HbA1c at 3 months. The ADA recommends HbA1c measurement every 3 months until the target is reached, then every 6 months for stable patients [5]. A meaningful HbA1c reduction (typically 0.8 to 1.5 percentage points on 1.5 mg weekly, based on AWARD trial data) should be visible by the first 3-month check [14].

Weight. Dulaglutide produces modest weight loss compared to semaglutide. In the AWARD-11 trial (N=1,842), patients on 4.5 mg dulaglutide weekly lost a mean 4.7 kg at 36 weeks versus 2.7 kg on 1.5 mg [15]. Iowa prescribers track weight at each visit.

Renal function. Annual CMP including creatinine and eGFR is standard for any patient with diabetes. More frequent monitoring (every 3 to 6 months) applies to patients with baseline CKD stage 3 or higher [5].

Gastrointestinal symptoms. Nausea, vomiting, and diarrhea are the most common side effects and typically peak in the first 4 weeks. Patients who cannot tolerate 1.5 mg may remain on 0.75 mg longer or switch to a different GLP-1 with a different titration schedule. If pancreatitis is suspected (persistent severe abdominal pain radiating to the back), dulaglutide must be discontinued and not restarted [1].

Thyroid palpation. Given the boxed warning regarding thyroid C-cell tumors observed in rodent studies (not confirmed in humans at therapeutic doses), clinicians palpate the thyroid at routine visits and act on any nodule or neck mass [1].

Iowa telehealth platforms schedule mandatory follow-up visits at 4 to 8 weeks post-initiation and at 3 months, with labs ordered in advance of each visit.